portfolio
portfolio
The EU Malaria Fund invested in a diverse set of Malaria projects, as well as in so-called "secondary exploitations" of these assets into different WHO priority diseases areas. During its tenure, it has financed the following malaria projects:
approach
The EU Malaria fund has worked with a portfolio of promising projects. Compared to Oncology, TB or HIV, there are only very few companies active in the Malaria domain. Those originated from technology transfer out of many of Europe’s leading research organizations, and were not yet invested in by a large pharmaceutical company. Here, we prefered to fund platform projects, allowing for secondary exploitations of their anti-malaria assets, for example into COVID-19 and other important under-served infectious diseases.
This portfolio has been built as a result of an open call originally published on kENUP`s website for two years, and now available on this website. The participants in the portfolio have been dedicated by the Scientific Advisory Council during its sessions held on March 4, 2019, June 20, 2019, April 22, 2020, August 26, 2020, and on December 18, 2020.
Being part of the fund’s portfolio granted companies the right to submit financing requests to the fund, following the fund’s operating procedures published in the Governance section of this website. Thus, companies included in the portfolio were not guaranteed to receive funding.
With the announcement made on July 26, 2021, the portfolio has been closed and no further companies are expected to be added to the portfolio.
companies in the portfolio
As of December 18, 2020, 17 companies with 30 independent projects have passed the Scientific Advisory Council's initial screening and are being invited to submit formal financing requests.
17 of these projects are vaccine candidates, vaccine-components or preventive mAbs, nine are novel therapeutics or therapeutic mAbs, three are diagnostics, and one project is in vector control.
The companies in the portfolio include AchilleS Vaccines
(part of the Siena vaccines hub), Deutsche Malaria GmbH
(with Tübingen University), Evotec SE
(licensed from Sanofi, under the joint - Evotec-led - infectious disease open innovation R&D platform), Global Access Diagnostics (with Mologic),Innovex Therapeutics S.L.
(with IS Global Barcelona), In2Care
(with London School of Hygiene and Tropical Medicine), Global Malaria Vaccines GmbH and OxYmmune Ltd., both spin-offs from Oxford University's
Jenner Institute
Laboratories, KELTICPharma
(with Glasgow University), Konica Minolta Austria
(with the University of Pretoria), Magnetrap (SA)
(with with Université de Mons and Université de Lyon 1), Sanaria, Inc., Serum Institute of India
(advised by Lion’s Head Global Partners), Sumaya Biotech
(with Heidelberg University), Takis Biotech S.r.l, (with Rottapharm Biotech S.r.l., IGEA S.p.A., and DPhar S.p.A.), VicuTec Biologicals GmbH
(with Max Planck Institute for Biophysical Chemistry and University Medical Center in Göttingen), as well as one confidential vaccine asset.
the pipeline
Additional projects have been reviewed according to the fund's operating procedures. During the investment period of the Fund, they have been presented to the Scientific Advisory Council. These projects included mAbs, other therapeutics, diagnostics and vaccines. As of July 26, 2021, the Fund's portfolio is closed, no further companies will be added and no further financing of companies initiated.
